We at CoA Therapeutics know that this is a difficult time for all families, and that current circumstances often pose increased challenges on families caring for children with chronic diseases such as pantothenate kinase associated neurodegeneration (PKAN), propionic acidemia, methylmalonic acidemia and other inborn errors of metabolism We hope that you are all doing well and are taking care.
We want to assure you that we remain as committed as ever to moving forward with our program to develop our small molecule therapy for children living with PKAN, propionic acidemia, methylmalonic acidemia, and other diseases associated with CoA sequestration. But we also must acknowledge that we are facing unforeseen challenges with this global pandemic.
Our team is working from home, as are many around the world, and we continue be in close contact with our investigators at St Jude and internationally. We are continuing to conduct our toxicology studies in animals and other activities that will drive us toward an IND-submission.
We remain committed to the NBIA and organic acidemia communities and, first and foremost, to the safety of children and families living with these disorders. We will keep you up to date as the situation evolves and inform you of key developments from CoA Therapeutics and BridgeBio.
We would like to invite you to read a message from Neil Kumar, the CEO of BridgeBio, our parent company: https://bridgebio.com/news/an-open-letter-to-patients-and-their-families-from-bridgebio-pharma-ceo-neil-kumar
In the meantime, we wish you well. Please stay safe. We are in this together, and despite the uncertainty about what the future holds, we will continue to work as fast and diligently as we possibly can to support patients. If you would like further information or have any questions, please do not hesitate to contact us at email@example.com
Anna Wade, PhD,
VP of BD and Operations